Filing exhibits
- 8-K Current report
- 3.1 Second Amended and Restated Certificate of Incorporation of the Company
- 3.2 Amended and Restated Bylaws of the Company
- 4.1 Registration Rights Agreement, Dated September 9, 2021, by and Among the Company, Blue Water Sponsor LLC and Legacy Clarus Securityholders Party Thereto
- 10.2 Form of Indemnification Agreement (Directors)
- 10.3 Form of Indemnification Agreement (Officers)
- 10.4 Employment Agreement, Dated September 9, 2021, by and Between Clarus Therapeutics, Inc. and Robert E. Dudley
- 10.5 Employment Agreement, Dated September 9, 2021, by and Between Clarus Therapeutics, Inc. and Richard Peterson
- 10.6 Employment Agreement, Dated September 9, 2021, by and Between Clarus Therapeutics, Inc. and Steven A. Bourne
- 10.7 Employment Agreement, Dated September 9, 2021, by and Between Clarus Therapeutics, Inc. and Frank Jaeger
- 10.9 Forms of Award Agreements Under the 2021 Stock Option and Incentive Plan
- 10.15 Supplemental Indenture No. 2, Dated September 9, 2021 by and Between Clarus Therapeutics, Inc. and U.S. Bank National Association
- 16.1 Marcum's Letter to the Securities and Exchange Commission, Dated September 15, 2021.
- 99.1 Unaudited Interim Financial Statements of Legacy Clarus As of and for the Six Months Ended June 30, 2021
- 99.2 Management's Discussion and Analysis of Financial Condition and Results of Operations of Legacy Clarus for the Six Months Ended June 30, 2021
- 99.3 Unaudited Pro Forma Condensed Combined Financial Information of the Company As of and for the Six Months Ended June 30, 2021 and for the Year Ended December 31, 2020
- Download Excel data file
- View Excel data file
Table of Contents